FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2082547513> ?p ?o ?g. }

• W2082547513 endingPage "679" @default.
• W2082547513 startingPage "673" @default.
• W2082547513 abstract "PurposeSouthwest Oncology Group 9504 demonstrated the feasibility and potential benefit of docetaxel consolidation after etoposide, cisplatin, and radiotherapy in patients with locally advanced non-small cell lung cancer. Our study assessed consolidation with either gemcitabine alone or with docetaxel after identical chemoradiation as used in Southwest Oncology Group 9504.MethodsPatients with stage III non-small cell lung cancer and good performance status were included. Treatment consisted of concurrent cisplatin 50 mg/m2 on days 1 and 8 plus etoposide 50 mg/m2 on days 1 to 5 for two 28-day cycles plus radiotherapy (62 Gy, 2 Gy daily in 31 fractions over 7 weeks), followed by randomization to either gemcitabine 1000 mg/m2 on days 1 and 8 (G) or gemcitabine 1000 mg/m2 on days 1 and 8 plus docetaxel 75 mg/m2 on day 1 (GD) every 21 days for three cycles.ResultsEighty-three patients were entered, 81 received induction therapy, and 64 were randomized (32 in each arm). Grade 3 or four events, including neutropenia (56.3% vs. 28.1%, p = 0.03), anemia (18.8% vs. 3.1%, p = 0.05), and fatigue (15.6% vs. 6.3%, p = NS), were more frequent with GD compared with G. Among all patients, median survival from registration was 20.8 months (95% confidence interval: 16.4–33.8), and 2-year survival was 46.7% (95% confidence interval: 35.6–57.1). From randomization, median progression-free survival was 5.4 months for G and 13.4 months for GD, and median survival was 16.1 months for G and 29.5 months for GD. Two-year survival rates were 40.6% for G and 55.7% for GD.ConclusionThe doublet, as expected, resulted in more toxicity, particularly myelosuppression and fatigue. Survival associated with the GD treatment arm of this trial exceeds that of previously reported trials. Southwest Oncology Group 9504 demonstrated the feasibility and potential benefit of docetaxel consolidation after etoposide, cisplatin, and radiotherapy in patients with locally advanced non-small cell lung cancer. Our study assessed consolidation with either gemcitabine alone or with docetaxel after identical chemoradiation as used in Southwest Oncology Group 9504. Patients with stage III non-small cell lung cancer and good performance status were included. Treatment consisted of concurrent cisplatin 50 mg/m2 on days 1 and 8 plus etoposide 50 mg/m2 on days 1 to 5 for two 28-day cycles plus radiotherapy (62 Gy, 2 Gy daily in 31 fractions over 7 weeks), followed by randomization to either gemcitabine 1000 mg/m2 on days 1 and 8 (G) or gemcitabine 1000 mg/m2 on days 1 and 8 plus docetaxel 75 mg/m2 on day 1 (GD) every 21 days for three cycles. Eighty-three patients were entered, 81 received induction therapy, and 64 were randomized (32 in each arm). Grade 3 or four events, including neutropenia (56.3% vs. 28.1%, p = 0.03), anemia (18.8% vs. 3.1%, p = 0.05), and fatigue (15.6% vs. 6.3%, p = NS), were more frequent with GD compared with G. Among all patients, median survival from registration was 20.8 months (95% confidence interval: 16.4–33.8), and 2-year survival was 46.7% (95% confidence interval: 35.6–57.1). From randomization, median progression-free survival was 5.4 months for G and 13.4 months for GD, and median survival was 16.1 months for G and 29.5 months for GD. Two-year survival rates were 40.6% for G and 55.7% for GD. The doublet, as expected, resulted in more toxicity, particularly myelosuppression and fatigue. Survival associated with the GD treatment arm of this trial exceeds that of previously reported trials." @default.
• W2082547513 created "2016-06-24" @default.
• W2082547513 creator A5002341560 @default.
• W2082547513 creator A5003839820 @default.
• W2082547513 creator A5004625690 @default.
• W2082547513 creator A5016064449 @default.
• W2082547513 creator A5017691590 @default.
• W2082547513 creator A5027610105 @default.
• W2082547513 creator A5030169080 @default.
• W2082547513 creator A5049504224 @default.
• W2082547513 creator A5071644999 @default.
• W2082547513 creator A5090256464 @default.
• W2082547513 date "2010-05-01" @default.
• W2082547513 modified "2023-10-15" @default.
• W2082547513 title "Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B Unresectable Non-small Cell Lung Cancer" @default.
• W2082547513 cites W1550111394 @default.
• W2082547513 cites W1817196311 @default.
• W2082547513 cites W1865725105 @default.
• W2082547513 cites W1883860222 @default.
• W2082547513 cites W1898871412 @default.
• W2082547513 cites W1930978022 @default.
• W2082547513 cites W1944220675 @default.
• W2082547513 cites W2035704169 @default.
• W2082547513 cites W2090285521 @default.
• W2082547513 cites W2104325484 @default.
• W2082547513 cites W2105024669 @default.
• W2082547513 cites W2105969273 @default.
• W2082547513 cites W2106672370 @default.
• W2082547513 cites W2139248078 @default.
• W2082547513 cites W2140469315 @default.
• W2082547513 cites W2312703485 @default.
• W2082547513 cites W2336518291 @default.
• W2082547513 cites W2346194474 @default.
• W2082547513 cites W4293241248 @default.
• W2082547513 doi "https://doi.org/10.1097/jto.0b013e3181d60e8f" @default.
• W2082547513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20354453" @default.
• W2082547513 hasPublicationYear "2010" @default.
• W2082547513 type Work @default.
• W2082547513 sameAs 2082547513 @default.
• W2082547513 citedByCount "15" @default.
• W2082547513 countsByYear W20825475132012 @default.
• W2082547513 countsByYear W20825475132013 @default.
• W2082547513 countsByYear W20825475132014 @default.
• W2082547513 countsByYear W20825475132015 @default.
• W2082547513 countsByYear W20825475132017 @default.
• W2082547513 countsByYear W20825475132018 @default.
• W2082547513 countsByYear W20825475132021 @default.
• W2082547513 countsByYear W20825475132022 @default.
• W2082547513 crossrefType "journal-article" @default.
• W2082547513 hasAuthorship W2082547513A5002341560 @default.
• W2082547513 hasAuthorship W2082547513A5003839820 @default.
• W2082547513 hasAuthorship W2082547513A5004625690 @default.
• W2082547513 hasAuthorship W2082547513A5016064449 @default.
• W2082547513 hasAuthorship W2082547513A5017691590 @default.
• W2082547513 hasAuthorship W2082547513A5027610105 @default.
• W2082547513 hasAuthorship W2082547513A5030169080 @default.
• W2082547513 hasAuthorship W2082547513A5049504224 @default.
• W2082547513 hasAuthorship W2082547513A5071644999 @default.
• W2082547513 hasAuthorship W2082547513A5090256464 @default.
• W2082547513 hasBestOaLocation W20825475131 @default.
• W2082547513 hasConcept C126322002 @default.
• W2082547513 hasConcept C143998085 @default.
• W2082547513 hasConcept C168563851 @default.
• W2082547513 hasConcept C204243189 @default.
• W2082547513 hasConcept C207103383 @default.
• W2082547513 hasConcept C2776256026 @default.
• W2082547513 hasConcept C2776694085 @default.
• W2082547513 hasConcept C2777063308 @default.
• W2082547513 hasConcept C2778119113 @default.
• W2082547513 hasConcept C2778239845 @default.
• W2082547513 hasConcept C2780258809 @default.
• W2082547513 hasConcept C2781190966 @default.
• W2082547513 hasConcept C44249647 @default.
• W2082547513 hasConcept C71924100 @default.
• W2082547513 hasConcept C90924648 @default.
• W2082547513 hasConceptScore W2082547513C126322002 @default.
• W2082547513 hasConceptScore W2082547513C143998085 @default.
• W2082547513 hasConceptScore W2082547513C168563851 @default.
• W2082547513 hasConceptScore W2082547513C204243189 @default.
• W2082547513 hasConceptScore W2082547513C207103383 @default.
• W2082547513 hasConceptScore W2082547513C2776256026 @default.
• W2082547513 hasConceptScore W2082547513C2776694085 @default.
• W2082547513 hasConceptScore W2082547513C2777063308 @default.
• W2082547513 hasConceptScore W2082547513C2778119113 @default.
• W2082547513 hasConceptScore W2082547513C2778239845 @default.
• W2082547513 hasConceptScore W2082547513C2780258809 @default.
• W2082547513 hasConceptScore W2082547513C2781190966 @default.
• W2082547513 hasConceptScore W2082547513C44249647 @default.
• W2082547513 hasConceptScore W2082547513C71924100 @default.
• W2082547513 hasConceptScore W2082547513C90924648 @default.
• W2082547513 hasIssue "5" @default.
• W2082547513 hasLocation W20825475131 @default.
• W2082547513 hasLocation W20825475132 @default.
• W2082547513 hasOpenAccess W2082547513 @default.
• W2082547513 hasPrimaryLocation W20825475131 @default.
• W2082547513 hasRelatedWork W2081815287 @default.
• W2082547513 hasRelatedWork W2118940674 @default.
• W2082547513 hasRelatedWork W2135497551 @default.

• next